Cargando…

Safety and efficacy of nivolumab plus recombinant human endostatin in previously treated advanced non-small-cell lung cancer

BACKGROUND: Evidence of the efficacy of immune checkpoint inhibitors (ICIs) plus antiangiogenic drugs in previously treated patients with advanced non-small-cell lung cancer (NSCLC) is still insufficient, so we investigated the safety and efﬁcacy of nivolumab plus recombinant human (rh)-endostatin i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Weize, Pei, Xiaofeng, Zhao, Wenhua, Cong, Yunyan, Wei, Yajun, Li, Ting, Zhang, Hongyu, Lin, Zhong, Saito, Yuichi, Kim, Jae Jun, Liang, Zibin, Zhong, Beilong, Wang, Zhihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2022
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8902090/ https://www.ncbi.nlm.nih.gov/pubmed/35280309 http://dx.doi.org/10.21037/tlcr-22-49

Ejemplares similares

Treatment Patterns and Survival of Patients With Advanced Non-Small Cell Lung Cancer Guided by Comprehensive Genomic Profiling: Real-World Single-Institute Study in China
por: Lv, Weize, et al.
Publicado: (2021)

Clinical effects of cisplatin plus recombinant human endostatin (rh-endostatin) intratumoral injection on malignant central airway obstruction: a retrospective analysis of 319 cases
por: Zhou, Yunzhi, et al.
Publicado: (2021)

Immunotherapy combined with rh-endostatin improved clinical outcomes over immunotherapy plus chemotherapy for second-line treatment of advanced NSCLC
por: Huang, Hongxiang, et al.
Publicado: (2023)

Antiangiogenic effects of recombinant human endostatin in lung cancers
por: He, Lang, et al.
Publicado: (2018)

miR-204-5p inhibits cell proliferation and induces cell apoptosis in esophageal squamous cell carcinoma by regulating Nestin
por: Luo, Honghe, et al.
Publicado: (2022)

Case Report: Recombinant Human Endostatin Plus Chemotherapy for Epidermal Growth Factor Receptor-Negative Miliary Lung Adenocarcinoma
por: Zhu, Jian, et al.
Publicado: (2022)

Efficacy of Recombinant Human Endostatin plus Neoadjuvant Chemotherapy for Osteosarcoma and Its Influence on Serum VEGF and MMP-9 Levels
por: Sui, Wei, et al.
Publicado: (2023)

Continuous intravenous infusion of recombinant human endostatin using infusion pump plus chemotherapy in non-small cell lung cancer
por: Qin, Zhi-Quan, et al.
Publicado: (2022)

Endostatin in the pancreas
por: Wigmore, S J
Publicado: (2005)

Recombinant human endostatin in combination with CHOP regimen for peripheral T cell lymphoma
por: Zhang, Qunling, et al.
Publicado: (2016)

The accumulation of macrophages attenuates the effect of recombinant human endostatin on lung cancer
por: Liu, Yanyang, et al.
Publicado: (2016)

Recombinant human endostatin combined with radiotherapy inhibits colorectal cancer growth
por: Zhang, Ke, et al.
Publicado: (2017)

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment
por: Li, Kai, et al.
Publicado: (2018)

Comparisons of biophysical properties and bioactivities of mono-PEGylated endostatin and an endostatin analog
por: Wang, Shan, et al.
Publicado: (2016)

Performance of Pretreatment MRI-Based Radiomics in Recombinant Human Endostatin Plus Concurrent Chemoradiotherapy Response Prediction in Nasopharyngeal Carcinoma: A Retrospective Study
por: Huang, Lixuan, et al.
Publicado: (2023)

Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome
por: Bachelot, T, et al.
Publicado: (2006)

Combining therapy with recombinant human endostatin and cytotoxic agents for recurrent disseminated glioblastoma: a retrospective study
por: Ge, Jing-jing, et al.
Publicado: (2020)

Clinical observation of Pemetrexed first-line treatment in advanced non-squamous lung cancer or non-small cell lung cancer without driver-mutations: a phase 2, single-arm trial
por: Sha, Zhou, et al.
Publicado: (2020)

Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
por: Chapman, Paul B, et al.
Publicado: (2021)

Recombinant Human Endostatin Endostar Suppresses Angiogenesis and Lymphangiogenesis of Malignant Pleural Effusion in Mice
por: Ma, Xingqun, et al.
Publicado: (2012)

The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering
por: Mohajeri, Abbas, et al.
Publicado: (2017)

Recombinant Endostatin as a Potential Radiosensitizer in the Treatment of Non-Small Cell Lung Cancer
por: Cunningham, Charnay, et al.
Publicado: (2023)

A new path for endostatin
por: Dove, Alan W.
Publicado: (2002)

Gene therapy of renal cancer using recombinant adeno-associated virus encoding human endostatin
por: Sun, Erlin, et al.
Publicado: (2018)

Efficacy and safety of rh‐endostatin (Endostar) combined with pemetrexed/cisplatin followed by rh‐endostatin plus pemetrexed maintenance in non‐small cell lung cancer: A retrospective comparison with standard chemotherapy
por: Zhou, Shengyu, et al.
Publicado: (2018)

Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
por: Gettinger, Scott N., et al.
Publicado: (2021)

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients
por: Shiono, Ayako, et al.
Publicado: (2019)

Nivolumab plus ipilimumab in the treatment of advanced melanoma
por: Tsai, Katy K., et al.
Publicado: (2015)

Stereotaktische Radiotherapie plus Nivolumab bei NSCLC
por: Krug, David, et al.
Publicado: (2023)

Enhancement of Recombinant Human Endostatin on the Radiosensitivity of Human Pulmonary Adenocarcinoma A549 Cells and Its Mechanism
por: Jiang, Xiao-dong, et al.
Publicado: (2012)

Differential effects of recombinant human endostatin treatment on differentiated and undifferentiated blood vessels in Lewis lung cancer
por: Fu, Weijiang, et al.
Publicado: (2017)

Recombined humanized endostatin‐induced suppression of HMGB1 expression inhibits proliferation of NSCLC cancer cells
por: Meng, Fan‐Jie, et al.
Publicado: (2018)

Recombined humanized endostatin (Endostar) intravenous infusion in the treatment of refractory nasopharyngeal carcinoma: Three case reports
por: Chen, Chen, et al.
Publicado: (2019)

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV
por: Xing, Peipei, et al.
Publicado: (2016)

The effect of ifosfamide, epirubicin, and recombinant human endostatin therapy on a cardiac angiosarcoma: A case report
por: Jiang, Lijun, et al.
Publicado: (2019)

Recombinant human endostatin combined with chemotherapy for advanced squamous cell lung cancer: a meta-analysis
por: Feng, Li, et al.
Publicado: (2021)

Comparison of the antiangiogenic activity of modified RGDRGD-endostatin to endostatin delivered by gene transfer in vivo rabbit neovascularization model
por: Ge, Hong-yan, et al.
Publicado: (2011)

Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma
por: Diab, Adi, et al.
Publicado: (2021)

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer
por: Shitara, Kohei, et al.
Publicado: (2022)

Risk of immune-related adverse events associated with ipilimumab-plus-nivolumab and nivolumab therapy in cancer patients
por: Zhou, Shi, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ruc0bgvki1esi8h5g8hr94amaf